Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler®

British Journal of Clinical Pharmacology

Volumn 48, Issue 3, 1999, Pages 309-316

  Kaiser, H ^a   Aaronson, D ^b   Dockhorn, R ^c   Edsbacker S ^d   Korenblat, P ^e   Kallen A ^f  

^a Allergy and Asthma Specialists   (United States)

^b Aaronson Asthma and Allerg Assoc   (United States)

^c Intl Med Tech Consultants Inc   (United States)

^d Pharmacological Laboratory   (Sweden)

^e Internal Medicine   (United States)

^f Biostatistics and Data Processing   (Sweden)

Author keywords

Budesonide; Pharmacokinetics; Turbuhaler

Indexed keywords

BUDESONIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HOARSENESS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MENORRHAGIA; MULTICENTER STUDY; NOSE CONGESTION; PHARYNGITIS; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RHINITIS; SORE THROAT; STOMACH PAIN;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; POWDERS;

EID: 0032821388     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00008.x     Document Type: Article

References (28)

1. Toogood JH, Frankish CW, Jennings BH, et al. A study of the mechanism of the antiasthmatic action of inhaled budesonide. J Allergy Clin Immunol 1990; 85: 872-880.
2. Reed CE. Aerosol steroids as primary treatment of mild asthma. N Engl J Med 1991; 325: 425-426.
3. Brattsand R, Thalén A, Roempke K, Källström Gruvstad L. New glucocorticoids with improved ratio between topical and systemic activities. Br J Pharmacol 1982; 77: 4433P.
4. Ellul-Micallef R, Hansson E, Johansson SÅ. Budesonide: a new corticosteroid in bronchial asthma. Eur J Respir Dis 1980; 61: 167-173.
5. Ellul-Micallef R, Hansson E, Johansson SÅ. Acute dose-response studies in bronchial asthma with a new corticosteroid, budesonide. Br J Clin Pharmacol 1983; 15: 419-422.
6. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a agonist, terbutaline, with an inhaled corticosteroid, budesonide in newly detected asthma. N Engl J Med 1991; 325: 388-392.
7. Brattsand R, Pipkorn U. Glucocorticoids: experimental approaches. In Asthma: its Pathology and Treatment, eds Kaliner MA, Barnes PJ, Persson CGA, New York: Marcel Dekker Inc, 1991: 667-709.
8. Andersson P, Ryrfeldt Å. Biotransformation of the topical glucocorticosteroids budesonide and beclomethosone 17α, 21-dipropionate in human liver and lung homogenate. J Pharm Pharmacol 1984; 36: 763-765.
9. Dahlberg E, Thalén A, Brattsand R, et al. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active 16-alpha, 17-alpha-acetyl substituted glucocorticoids. Mol Pharmacol 1984; 25: 70-78.
10. Edsbäcker S, Jönsson S, Lindberg C, Ryrfeldt Å, Thaldén A. Metabolic pathways of the topical glucocorticoid, budesonide, in man. Drug Metab Dispos 1983; 11: 590-596.
11. Thorsson L, Edsbäcker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler is twice that from pressurised metered dose inhaler P MDI. Eur Respir J 1994; 7: 1839-1844.
12. Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996; 153: 1636-1640.
13. Brambilla C, Lacronique J, Allaert FA, Godard P, Duroux P. A 3-month comparative dose-reduction study with inhaled beclomethasone dipropionate and budesonide in the management of moderate to severe adult asthma. Drug Invest 1994; 8: 49-56.
14. Grahnén A, Eckenäs S-Å, Brundin RM, Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 1994; 38: 521-525.
15. Sclroos O, Backman R, Forsén KO, et al. Local side-effects during 4-year treatment with inhaled corticosteroids - a comparison between pressurized metered dose inhalers and Turbuhaler™. Allergy 1994; 49: 888-890.
16. Agertoft L, Pedersen S. Importance of inhalation device on the effect of budesonide. Arch Dis Child 1993; 69: 130-133.
17. Aaronson D, Kaiser H, Dockhorn R, et al. Effects of budesonide by means of Turbuhaler on HPA-axis in asthmatic subjects. J Allergy Clin Immunol 1998; 101: 312-319.
18. Lindberg C, Blomqvist A, Paulson J. Determination of (22R,S) budesonide in human plasma by automated liquid chromatography/thermospray mass spectrometry. Biol Mass Spectrometry 1992; 2: 525-533.
19. Ryrfeldt Å, Andersson P, Edsbäcker S, et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982; 63(Suppl 122): 86-95.
20. Liard R, Aubier M, Zureik M, Neukirch F. Advantage of breath-actuated inhalers versus metered-dose inhalers. Eur Respir J 1995; 8: 2195.
21. Thorsson L, Dahlström K, EdsBäcker S, Källén A, Wirén J-E. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997; 43: 155-161.
22. Lönnebo A, Grahnén A, Jansson B, Brundin RM, Ling-Andersson A, Eckernäs S-A. An assessment of the systemic activity of single and repeated doses of inhaled fluticasone propionate and budesonide in healthy volunteers. Eur J Clin Pharmacol 1996; 49: 459-463.
23. Brown PH, Ning AC, Greening AP, McLean A, Crompton GK. Peak inspiratory flow through Turbuhaler in acute asthma. Eur Respir J 1995; 8: 1940-1941.
24. Thorsson L, Kenyon C, Newman S, Borgström L. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int J Pharmaceut 1998 1; 68: 119-127.
25. Wieslander E, Delander E-L, Järkelid L, Hjertberg F., Tunek A, Brattsand R. Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line in vitro. Am J Resp Cell Mol Biol 1998; 19: 477-484.
26. Miller-Larsson A, Mattson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide: novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998; 26 (7): 623-630.
27. Thalén A, Brattsand R, Gruvstad E. Synthesis and pharmacological properties of some 16alpha, 17alpha-acetals of 16alpha-hydroxyhydrocortisone, 16alpha hydroxyprednisolone and fluorinated 16alpha-hydroxyprednisolones. Acta Pharm Suec 1984; 21: 109-124.
28. Ryrfeldt Å, Edsbäcker S, Pauwels R. Kinetics of the epimeric glucocorticoid budesonide. Clin Pharmacol Ther 1984; 35: 525-530.